Matthew Lorence has extensive experience in the therapeutics, genomics and molecular diagnostic industries and is currently CEO at Chimera Therapeutics, a City of Hope startup focusing on blood and autoimmune disorders. He most recently served as CEO of CDR3 Therapeutics, as President and CEO of Edge Biosystems and as SVP, Global Marketing at Calibre Scientific. His consulting experience encompasses the assessment of molecular products and services companies for acquisition by a leading life sciences private equity firm, development of a RADx-funded COVID-19 mobile testing system, and the at-home COVID-19 molecular test market opportunity, as well as serving as an external grant reviewer for Grand Challenges Canada. He earned both a PhD degree in Molecular Biology and an MBA degree in Marketing from the University of Texas at Dallas and received an NIH Postdoctoral Fellowship while in the Departments of Biochemistry and Obstetrics-Gynecology at the University of Texas Southwestern Medical Center at Dallas. Dr. Lorence has authored more than 20 peer-reviewed publications and has extensive FDA experience.